Kevin Walton

Kevin Walton is an accomplished executive with extensive experience in corporate development and business strategy in the biotechnology and pharmaceutical sectors. Currently serving as Chief Executive Officer and Board Director at Baseimmune since 2025, Walton has also held significant roles such as Chief Business Officer, Senior Director of Corporate Development at Moderna, and Vice President of Corporate Development at StrideBio, Inc., which was acquired by Ginkgo in 2023. Previous positions include Senior Director of Business Development at Curis, Director of Corporate Development & Strategy at G1 Therapeutics, and roles at Amgen, Eli Lilly, Ceramedix, Torreya Partners, and Charles River Associates. Walton holds a Juris Doctor degree magna cum laude from Duke University School of Law, an MBA from Duke University’s Fuqua School of Business as a Fuqua Scholar, and a Bachelor of Arts degree magna cum laude in Economics and History from Boston College.